Related Experiment Video

Updated: Apr 8, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K

Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation

Amjid Iqbal1, Fatima Rodriguez, Henrik Schirmer

  • 1Division of Cardiothoracic and Respiratory Medicine, Department of Cardiology, University Hospital of North Norway, Tromso, Norway, amjid.iqbal@unn.no.

Current Cardiology Reports
|June 25, 2015
PubMed

Insights

Novel oral anticoagulants offer more options for atrial fibrillation (Afib) patients needing anticoagulation. Managing these patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) requires careful consideration of antiplatelet and anticoagulant therapies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Novel oral anticoagulants (NOACs) have become preferred over vitamin K antagonists for anticoagulation in atrial fibrillation (Afib).
  • Many aging Afib patients develop stable coronary artery disease (CAD) requiring antiplatelet therapy alongside anticoagulation.
  • Managing antithrombotic therapy becomes complex during and after percutaneous coronary intervention (PCI) in Afib patients with CAD.

Purpose of the Study:

  • To review the scientific rationale behind current guidelines for antithrombotic therapy in Afib patients with stable CAD.
  • To provide guidance on anticoagulation and antiplatelet management before, during, and after elective PCI.

Main Methods:

  • Review of recent scientific literature and clinical guidelines.
  • Analysis of pharmacological interactions and clinical outcomes.

Main Results:

  • Guidelines increasingly incorporate NOACs for Afib patients with CAD.
  • Optimal timing and combination of anticoagulation and antiplatelet therapy are crucial for balancing thrombotic and bleeding risks.
  • Specific recommendations exist for managing antithrombotic therapy around PCI procedures.

Conclusions:

  • Evidence-based guidelines help navigate complex antithrombotic strategies in Afib patients with CAD undergoing PCI.
  • Individualized treatment plans are essential to optimize patient outcomes.
  • Further research may refine optimal therapeutic durations and combinations.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
594
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
419
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
429
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
478
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654